Eli Lilly and Company (NYSE:LLY) Shares Sold by Mitsubishi UFJ Trust & Banking Corp

Mitsubishi UFJ Trust & Banking Corp reduced its stake in Eli Lilly and Company (NYSE:LLY) by 1.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 447,110 shares of the company’s stock after selling 7,137 shares during the period. Eli Lilly and Company makes up about 1.0% of Mitsubishi UFJ Trust & Banking Corp’s investment portfolio, making the stock its 11th biggest holding. Mitsubishi UFJ Trust & Banking Corp’s holdings in Eli Lilly and Company were worth $369,273,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the stock. Mirabaud & Cie SA acquired a new stake in Eli Lilly and Company in the 1st quarter valued at $4,697,000. Endeavor Private Wealth Inc. acquired a new stake in Eli Lilly and Company in the 1st quarter valued at $227,000. Fiduciary Wealth Partners LLC acquired a new stake in Eli Lilly and Company in the 1st quarter valued at $218,000. IFG Advisory LLC increased its holdings in Eli Lilly and Company by 20.8% in the 1st quarter. IFG Advisory LLC now owns 3,727 shares of the company’s stock valued at $3,078,000 after purchasing an additional 641 shares in the last quarter. Finally, Strategic Family Wealth Counselors L.L.C. increased its holdings in Eli Lilly and Company by 14.0% in the 1st quarter. Strategic Family Wealth Counselors L.L.C. now owns 309 shares of the company’s stock valued at $255,000 after purchasing an additional 38 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $761.47 on Friday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The company’s 50-day simple moving average is $775.51 and its 200-day simple moving average is $799.86. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The stock has a market capitalization of $721.68 billion, a price-to-earnings ratio of 61.96, a PEG ratio of 1.05 and a beta of 0.44.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The business had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. During the same period in the prior year, the business earned $2.58 EPS. The business’s revenue was up 45.2% on a year-over-year basis. Equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 48.82%.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on LLY shares. The Goldman Sachs Group raised shares of Eli Lilly and Company from a “neutral” rating to a “buy” rating and decreased their price objective for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. Erste Group Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research report on Thursday, June 5th. Cantor Fitzgerald started coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They issued an “overweight” rating and a $975.00 price objective for the company. Morgan Stanley reissued an “overweight” rating and issued a $1,135.00 price objective (up from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. Finally, Wall Street Zen raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $1,012.56.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.